- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Fredun Pharmaceuticals has announced a board meeting to discuss the financial results for the quarter and half-year. The company is a diversified pharma player with a strong presence in generics, nutraceuticals, cosmeceuticals, pet healthcare, and mobility segments. Its product portfolio includes 697 registered products in 52 countries and 1,200+ under registrations. The advanced Palghar facility continues to expand capacity, supporting growth in high-margin new-age products and international contracts. Key growth drivers include expansion in pet care with the launch of India’s first dedicated pet diagnostic centre and entry into large animal healthcare products. The company reported steady revenue growth to Rs 456.3 Cr in FY25 with improving profitability and ROCE of 12.1%.